In 3-year data from the CAPELLA study, the subcutaneous, long-acting capsid inhibitor lenacapavir (Sunlenca) demonstrated ...
Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback